Feasibility and safety of oupatient Bexxar® therapy (tositumomab and iodine I 131 tositumomab) for Non-Hodgkin's lymphoma based on radiation doses to family members

Frank J. Rutar, Samuel C. Augustine, Mark S. Kaminski, Richard L. Wahl, Jeffry A. Siegel, David Colcher

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Radioimmunotherapy with anti-CD20 antibodies is a promising treatment approach for relapsed low-grade non-Hodgkin's lymphoma. Under revised Nuclear Regulatory Commission regulations (May 1997), patients may be released following treatment provided the maximum dose to any individual is not likely to exceed 500 mrem. Non-Hodgkin's lymphoma patients have been studied to evaluate radiation exposure to caregivers/family members after outpatient treatment with tositumomab and iodine I 131 tositumomab (Bexxar® therapy). Estimates of total radiation doses to individuals expected to be maximally exposed to patients posttreatment have revealed that the doses should be within revised guidelines. In a University of Nebraska Medical Center study, the predicted total radiation doses (based on patient dose rate at 1 meter) ranged from 95-423 mrem. Family members were provided radiation-monitoring devices to directly monitor radiation exposure. Measured doses ranged from 10-409 mrem. In this and other studies, estimated and measured dose equivalents to maximally exposed individuals were below 500 mrem. Measured doses were, in most instances, lower than those predicted by patient-specific calculations, thus confirming the validity of the calculated dose predictions. Therefore, radioimmunotherapy with tositumomab and iodine I 131 tositumomab can be safely conducted on an outpatient basis.

Original languageEnglish
Pages (from-to)164-172
Number of pages9
JournalClinical Lymphoma
Volume2
Issue number3
StatePublished - 2001
Externally publishedYes

Fingerprint

Non-Hodgkin's Lymphoma
Radiation
Safety
Radioimmunotherapy
Outpatients
Radiation Monitoring
Therapeutics
Caregivers
Anti-Idiotypic Antibodies
iodine-131 anti-B1 antibody
Guidelines
Equipment and Supplies
Radiation Exposure

All Science Journal Classification (ASJC) codes

  • Cancer Research

Cite this

Feasibility and safety of oupatient Bexxar® therapy (tositumomab and iodine I 131 tositumomab) for Non-Hodgkin's lymphoma based on radiation doses to family members. / Rutar, Frank J.; Augustine, Samuel C.; Kaminski, Mark S.; Wahl, Richard L.; Siegel, Jeffry A.; Colcher, David.

In: Clinical Lymphoma, Vol. 2, No. 3, 2001, p. 164-172.

Research output: Contribution to journalArticle

Rutar, Frank J. ; Augustine, Samuel C. ; Kaminski, Mark S. ; Wahl, Richard L. ; Siegel, Jeffry A. ; Colcher, David. / Feasibility and safety of oupatient Bexxar® therapy (tositumomab and iodine I 131 tositumomab) for Non-Hodgkin's lymphoma based on radiation doses to family members. In: Clinical Lymphoma. 2001 ; Vol. 2, No. 3. pp. 164-172.
@article{a8c7d38263364271b1b3a107ccf1eb08,
title = "Feasibility and safety of oupatient Bexxar{\circledR} therapy (tositumomab and iodine I 131 tositumomab) for Non-Hodgkin's lymphoma based on radiation doses to family members",
abstract = "Radioimmunotherapy with anti-CD20 antibodies is a promising treatment approach for relapsed low-grade non-Hodgkin's lymphoma. Under revised Nuclear Regulatory Commission regulations (May 1997), patients may be released following treatment provided the maximum dose to any individual is not likely to exceed 500 mrem. Non-Hodgkin's lymphoma patients have been studied to evaluate radiation exposure to caregivers/family members after outpatient treatment with tositumomab and iodine I 131 tositumomab (Bexxar{\circledR} therapy). Estimates of total radiation doses to individuals expected to be maximally exposed to patients posttreatment have revealed that the doses should be within revised guidelines. In a University of Nebraska Medical Center study, the predicted total radiation doses (based on patient dose rate at 1 meter) ranged from 95-423 mrem. Family members were provided radiation-monitoring devices to directly monitor radiation exposure. Measured doses ranged from 10-409 mrem. In this and other studies, estimated and measured dose equivalents to maximally exposed individuals were below 500 mrem. Measured doses were, in most instances, lower than those predicted by patient-specific calculations, thus confirming the validity of the calculated dose predictions. Therefore, radioimmunotherapy with tositumomab and iodine I 131 tositumomab can be safely conducted on an outpatient basis.",
author = "Rutar, {Frank J.} and Augustine, {Samuel C.} and Kaminski, {Mark S.} and Wahl, {Richard L.} and Siegel, {Jeffry A.} and David Colcher",
year = "2001",
language = "English",
volume = "2",
pages = "164--172",
journal = "Clinical Lymphoma, Myeloma and Leukemia",
issn = "2152-2669",
publisher = "Cancer Media Group",
number = "3",

}

TY - JOUR

T1 - Feasibility and safety of oupatient Bexxar® therapy (tositumomab and iodine I 131 tositumomab) for Non-Hodgkin's lymphoma based on radiation doses to family members

AU - Rutar, Frank J.

AU - Augustine, Samuel C.

AU - Kaminski, Mark S.

AU - Wahl, Richard L.

AU - Siegel, Jeffry A.

AU - Colcher, David

PY - 2001

Y1 - 2001

N2 - Radioimmunotherapy with anti-CD20 antibodies is a promising treatment approach for relapsed low-grade non-Hodgkin's lymphoma. Under revised Nuclear Regulatory Commission regulations (May 1997), patients may be released following treatment provided the maximum dose to any individual is not likely to exceed 500 mrem. Non-Hodgkin's lymphoma patients have been studied to evaluate radiation exposure to caregivers/family members after outpatient treatment with tositumomab and iodine I 131 tositumomab (Bexxar® therapy). Estimates of total radiation doses to individuals expected to be maximally exposed to patients posttreatment have revealed that the doses should be within revised guidelines. In a University of Nebraska Medical Center study, the predicted total radiation doses (based on patient dose rate at 1 meter) ranged from 95-423 mrem. Family members were provided radiation-monitoring devices to directly monitor radiation exposure. Measured doses ranged from 10-409 mrem. In this and other studies, estimated and measured dose equivalents to maximally exposed individuals were below 500 mrem. Measured doses were, in most instances, lower than those predicted by patient-specific calculations, thus confirming the validity of the calculated dose predictions. Therefore, radioimmunotherapy with tositumomab and iodine I 131 tositumomab can be safely conducted on an outpatient basis.

AB - Radioimmunotherapy with anti-CD20 antibodies is a promising treatment approach for relapsed low-grade non-Hodgkin's lymphoma. Under revised Nuclear Regulatory Commission regulations (May 1997), patients may be released following treatment provided the maximum dose to any individual is not likely to exceed 500 mrem. Non-Hodgkin's lymphoma patients have been studied to evaluate radiation exposure to caregivers/family members after outpatient treatment with tositumomab and iodine I 131 tositumomab (Bexxar® therapy). Estimates of total radiation doses to individuals expected to be maximally exposed to patients posttreatment have revealed that the doses should be within revised guidelines. In a University of Nebraska Medical Center study, the predicted total radiation doses (based on patient dose rate at 1 meter) ranged from 95-423 mrem. Family members were provided radiation-monitoring devices to directly monitor radiation exposure. Measured doses ranged from 10-409 mrem. In this and other studies, estimated and measured dose equivalents to maximally exposed individuals were below 500 mrem. Measured doses were, in most instances, lower than those predicted by patient-specific calculations, thus confirming the validity of the calculated dose predictions. Therefore, radioimmunotherapy with tositumomab and iodine I 131 tositumomab can be safely conducted on an outpatient basis.

UR - http://www.scopus.com/inward/record.url?scp=0035544274&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035544274&partnerID=8YFLogxK

M3 - Article

VL - 2

SP - 164

EP - 172

JO - Clinical Lymphoma, Myeloma and Leukemia

JF - Clinical Lymphoma, Myeloma and Leukemia

SN - 2152-2669

IS - 3

ER -